Musculoskeletal
Temporomandibular Disorders
0
Pipeline Programs↗
5
Active Trials↗
1
Companies Involved↗
Temporomandibular Disorders is an early-stage landscape with 0 programs across 1 company. The most active players are Pfizer.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
No pipeline programs currently tracked for this disease.
Analysis
Trial Status
14
clinical trials
Completed7 · 50%
Terminated2 · 14%
Recruiting2 · 14%
Active, not recruiting1 · 7%
Enrolling by invitation1 · 7%
Not yet recruiting1 · 7%
Clinical Trials
Trial Activity
14 trials
Mandibular Splint vs Botox Injection in Lateral Pterygoid on Cervical Muscle Activity in Patients With Temporomandibular Disorders
Recruiting·—·N/A·NCT06553950·33 enrolled
Study of Etanercept and Celecoxib to Treat Temporomandibular Disorders (Painful Joint Conditions)
Completed·National Institute of Dental and Craniofacial Research (NIDCR)·Phase 2·NCT00001955·150 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)